A Phase II Simon Two-Stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI 2040 in Combination With High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML)).
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2015
At a glance
- Drugs LOR 2040 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 14 Jan 2011 This trial was completed in 2009, according to a Lorus Therapeutics media release
- 14 Jun 2010 Results presented at 15th Annual Congress of the European Hematology Association (EHA), according to a Lorus Therapeutics media release.
- 17 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.